Company news

Xencor, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Xencor Reports Second Quarter 2023 Financial Results

August 2, 2023

Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023

July 26, 2023

Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

May 29, 2023

Xencor Reports First Quarter 2023 Financial Results

May 7, 2023

Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023

April 30, 2023

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

April 25, 2023

Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

April 16, 2023

Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023

March 13, 2023

Xencor Reports Fourth Quarter and Full Year 2022 Financial Results

February 22, 2023

Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

February 15, 2023

Xencor to Present at the SVB Securities Global Biopharma Conference

February 6, 2023

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

January 8, 2023

Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates

January 4, 2023

Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting

December 11, 2022

Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting

November 9, 2022

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

November 6, 2022

Xencor Reports Third Quarter 2022 Financial Results

November 6, 2022

Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting

November 2, 2022

Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022

October 30, 2022

Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting

October 4, 2022

Xencor Appoints Nancy Valente, M.D., to Board of Directors

September 8, 2022

Xencor Reports Second Quarter 2022 Financial Results

August 2, 2022

Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies

August 1, 2022

Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022

July 26, 2022

Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

May 25, 2022

Xencor Reports First Quarter 2022 Financial Results

May 4, 2022

Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022

April 27, 2022

Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022

April 7, 2022

Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022

March 7, 2022

Xencor Reports Fourth Quarter and Full Year 2021 Financial Results

February 22, 2022

Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022

February 15, 2022

Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones

January 10, 2022

Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference

January 5, 2022

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

December 11, 2021

Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting

November 11, 2021

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting

November 11, 2021

Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306

November 7, 2021

Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting

November 3, 2021

Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium

November 2, 2021

Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021

October 31, 2021

Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies

October 3, 2021

Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting

September 30, 2021

Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference

September 19, 2021

Xencor Reports Second Quarter 2021 Financial Results

August 3, 2021

Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021

July 27, 2021

Xencor to Present at the Jefferies Virtual Healthcare Conference

May 26, 2021

Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19

May 25, 2021

Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

May 24, 2021

Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference

May 11, 2021

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 9 decks. Every deck is listed under its year.